You are here

Mitigating MSC-induced Blood Clotting

In a new STEM CELLS Translational Medicine article, researchers led by Rita N. Barcia (Sentien Biotechnologies, Inc, Lexington, Massachusetts, USA) demonstrate the use of a bioengineered device to mitigate the clotting effects of human mesenchymal stem cells (MSCs) behind a hollow fiber membrane. Hypercoagulable patients, including those in intensive care with COVID‐19, present a potential risk when intravenously injected with MSCs as a treatment option. While initial studies with MSCs have shown promising results for COVID‐19 infected patients on ventilators, reducing clot formation potential could broaden their application.